Nkarta Inc
Company Profile
Business description
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Contact
1150 Veterans Boulevard
South San FranciscoCA94080
USAT: +1 905 407-1049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
157
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,440.20 | 16.00 | -0.19% |
| CAC 40 | 7,770.48 | 176.61 | 2.33% |
| DAX 40 | 23,086.65 | 589.67 | 2.62% |
| Dow JONES (US) | 41,317.43 | 564.47 | 1.39% |
| FTSE 100 | 8,596.35 | 99.55 | 1.17% |
| HKSE | 22,504.68 | 385.27 | 1.74% |
| NASDAQ | 17,977.73 | 266.99 | 1.51% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,380.46 | 52.57 | 0.43% |
| S&P 500 | 5,686.67 | 82.53 | 1.47% |
| S&P/ASX 200 | 8,218.80 | 19.20 | -0.23% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |